NasdaqGS:DFTXPharmaceuticals
Is Definium Therapeutics (DFTX) Expensive As New GAD Study Sharpens Its Late Stage Case?
Definium Therapeutics (DFTX) is back in focus after releasing a large U.S. healthcare claims study on generalized anxiety disorder. The study highlights frequent treatment discontinuation, switching, and long therapy gaps for both newly diagnosed and established patients.
See our latest analysis for Definium Therapeutics.
Against this backdrop, Definium Therapeutics shares have cooled in the very short term, with a 1-day share price return of 3.13% and a 7-day share price return of 4.36%...